Abstract 3410: Discovery of prognostic factors in Ewing's sarcoma family of tumors by use of Intercohort co-analysis of public gene expression datasets

PURPOSE To analyze event-free survival (EFS) and prognostic factors in patients who present with Ewing's tumors (ET) of bone and synchronous pulmonary and/or pleural metastases (ppm). PATIENTS AND METHODS Of 1,270 patients (pts) registered at the continental office of the German/European Intergroup Cooperative Ewing's Sarcoma Studies (CESS81, CESS86, EICESS92), 114 were diagnosed ET with ppm. Patients underwent neoadjuvant therapy and local treatment of the primary tumor. Whole-lung irradiation 15 to 18 Gy was applied to 75 ppm-pts. EFS and 95% confidence intervals (CIs) were estimated according to the Kaplan-Meier method, and prognostic factors were analyzed by log-rank tests and Cox and logistic regression procedures. RESULTS On November 1, 1997, at a median time under study of 5.9 years, the 5-year EFS was 0.36 (95% CI, 0.26 to 0.46) and the 10-year EFS was 0.30 (95% CI, 0.19 to 0.41). Thirty-seven of 59 (63%) first relapses involved lung and/or pleura, and the lungs were the only site of relapse in 26 of 59 (44%) ppm-pts. Risk factors identified in univariate and multivariate tests were poor response of the primary tumor toward chemotherapy, metastatic lesions in both lungs, and treatment without additional lung irradiation. CONCLUSION Chemotherapy response of the primary tumor is a prognostic factor in patients with ET with ppm. Strategies of treatment intensification warrant further evaluation.

Download Full-text

Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma

International Journal of Cancer ◽

10.1002/ijc.20171 ◽

2004 ◽

Vol 110 (5) ◽

pp. 687-694 ◽

Cited By ~ 58

Author(s):

Claudia Baer ◽

Mattias Nees ◽

Stephen Breit ◽

Barbara Selle ◽

Andreas E. Kulozik ◽

...

Keyword(s):

Gene Expression ◽

Functional Annotation ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Mrna Gene ◽

Mrna Gene Expression

Download Full-text

Microarray analysis of Ewing’s sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy

European Journal of Cancer ◽

10.1016/j.ejca.2008.01.020 ◽

2008 ◽

Vol 44 (5) ◽

pp. 699-709 ◽

Cited By ~ 63

Author(s):

Karl-Ludwig Schaefer ◽

Martin Eisenacher ◽

Yvonne Braun ◽

Kristin Brachwitz ◽

Daniel H. Wai ◽

...

Keyword(s):

Gene Expression ◽

Microarray Analysis ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Gene Expression Signatures ◽

Resistance To Chemotherapy

Download Full-text

CCT6A, a Novel Prognostic Biomarker for Ewing's Sarcoma

10.21203/rs.3.rs-52492/v1 ◽

2020 ◽

Author(s):

Jie Jiang ◽

Chong Liu ◽

Guoyong Xu ◽

Tuo Liang ◽

Chaojie Yu ◽

...

Keyword(s):

Gene Expression ◽

Overall Survival ◽

Ewing Sarcoma ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

High Expression ◽

P Value ◽

Event Free Survival ◽

Free Survival ◽

Cox Regression Analysis

Abstract Background: Ewing's sarcoma (ES) is the second most prevalent malignancy among bone tissue tumors, and there is no adequate prognosis biomarker. The protein encoded by CCT6A is a molecular chaperone. Early studies have suggested that CCT6A is involved in the development of many cancers, however, there is no clear evidence of a role for CCT6A in ES.Methods: In this study, we performed a bioinformatics analysis of 32 Ewing sarcoma specimens from the GSE17618 dataset for differences in gene expression and overall survival, event-free survival, and gene expression in different subgroups. Results: After three screenings, we identified CCT6A as highly correlated with Ewing's sarcoma prognosis. Survival analysis showed low overall survival (OS) for CCT6A high expression (P=0.024). On the other hand, Cox regression analysis showed that CCT6A expression, event-free survival (EFS), and age were strongly associated with the prognosis of Ewing sarcoma, identified as independent poor prognostic biomarkers. (CCT6A: P=0.015; Age: P-value=0.026; EFS: P-value=0.001). Conclusion: The expression level of CCT6A is strongly associated with the prognosis of Ewing's sarcoma. High expression of the CCT6A gene may serve as a biomarker for poor prognosis in patients with Ewing's sarcoma.

Download Full-text

Functional Interactions in Transcription and Splicing of Ewing’s Sarcoma

ISRN Genetics ◽

10.5402/2013/184063 ◽

2013 ◽

Vol 2013 ◽

pp. 1-6 ◽

Cited By ~ 1

Author(s):

Roumiana Todorova

Keyword(s):

Gene Expression ◽

Experimental Data ◽

Fusion Proteins ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Dna Binding Proteins ◽

Chromosomal Translocations ◽

Functional Interactions ◽

Binding Partners ◽

Rna And Dna

Ewing’s sarcoma (EWS) protein is a member of the TET (TLS/EWS/TAF15) family of RNA and DNA-binding proteins with unknown cellular role. EWS protein is encoded by the EWS oncogene on chromosome 22q12, a target of chromosomal translocations in Ewing’s sarcoma tumors. The exact mechanism of EWS participation in gene expression and pathogenesis of the resulting cancers is not defined. The binding partners of native EWS and EWS fusion proteins (EFPs) are described schematically in a model, an attempt to link the transcription with the splicing. The experimental data about the partnerships of EWS and EFPs are summarized, which may lead to better understanding of their function.

Download Full-text

Faculty Opinions recommendation of Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108606.564688 ◽

2008 ◽

Author(s):

Michael Leahy

Keyword(s):

Gene Expression ◽

Microarray Analysis ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Gene Expression Signatures ◽

Resistance To Chemotherapy

Download Full-text

Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma

International Journal of Cancer ◽

10.1002/ijc.27472 ◽

2012 ◽

Vol 131 (9) ◽

pp. 2153-2164 ◽

Cited By ~ 44

Author(s):

Aleksandar Boro ◽

Kathya Prêtre ◽

Florian Rechfeld ◽

Verena Thalhammer ◽

Susanne Oesch ◽

...

Keyword(s):

Gene Expression ◽

Cell Survival ◽

Small Molecule ◽

Target Gene ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Target Gene Expression ◽

Small Molecule Screen

Download Full-text

Prognostic Factors in Ewing’s Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative Ewing’s Sarcoma Study Group

Journal of Clinical Oncology ◽

10.1200/jco.2000.18.17.3108 ◽

2000 ◽

Vol 18 (17) ◽

pp. 3108-3114 ◽

Cited By ~ 600

Author(s):

S.J. Cotterill ◽

S. Ahrens ◽

M. Paulussen ◽

H.F. Jürgens ◽

P.A. Voûte ◽

...

Keyword(s):

Prognostic Factors ◽

Bone Metastases ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Local Therapy ◽

Study Group ◽

Data Set ◽

Pädiatrische Onkologie ◽

Survival After Relapse ◽

Ewing’S Tumor

PURPOSE: To further elaborate on prognostic factors for Ewing’s sarcoma of bone and to document improvements in relapse-free survival (RFS) and trends in local therapy over the study period (1977 to 1993). PATIENTS AND METHODS: A retrospective analysis was performed on a combined Gesellschaft Für Pädiatrische Onkologie und Hämatologie/Cooperative Ewing Sarcoma Study and United Kingdom Children’s Cancer Study Group/Medical Research Council data set of 975 patients registered with the respective trial offices before the current collaborative European Intergroup Cooperative Ewing’s Sarcoma Study trial. Both groups independently undertook studies with similar chemotherapy during the period. RESULTS: The key adverse prognostic factor is metastases at diagnosis (5-year RFS, 22% of patients with metastases at diagnosis v 55% of patients without metastases at diagnosis; P < .0001). For the group with metastases, there was a trend for better survival for those with lung involvement compared with those with bone metastases or a combination of lung and bone metastases (P < .0001). In the group of patients with no metastases at diagnosis, multivariate analysis demonstrated that site (axial v other), age-group (< 15 v ≥ 15 years), and period of diagnosis had significant influence on RFS (all P < .005). RFS was superior in the period after 1985 compared with the period before 1985 for nonmetastatic patients (45% v 60%, respectively; P < .0001) and for metastatic patients (16% v 30%, respectively; P = .016). Patients who relapsed within 2 years of diagnosis had a less favorable prognosis than patients who relapsed later (5-year survival after relapse, 4% v 23%, respectively; P < .0001). There were other changes over the period; in particular, radiotherapy or amputation were more common in the period before 1986, whereas endoprosthetic surgery was widely used in the later period. CONCLUSION: Survival and RFS improved over the period. Prognostic factors are metastases at diagnosis, primary site, and age.

Download Full-text